Investors focused on the Medical space have likely heard of Taro Pharmaceutical Industries (TARO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of TARO and the rest of the Medical group's stocks.
Taro Pharmaceutical Industries is a member of the Medical sector. This group includes 762 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. TARO is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for TARO's full-year earnings has moved 13.10% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, TARO has gained about 8.93% so far this year. At the same time, Medical stocks have gained an average of 0.73%. As we can see, Taro Pharmaceutical Industries is performing better than its sector in the calendar year.
To break things down more, TARO belongs to the Medical - Drugs industry, a group that includes 163 individual companies and currently sits at #108 in the Zacks Industry Rank. Stocks in this group have gained about 4.50% so far this year, so TARO is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to TARO as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Taro Pharmaceutical Industries (TARO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of TARO and the rest of the Medical group's stocks.
Taro Pharmaceutical Industries is a member of the Medical sector. This group includes 762 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. TARO is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for TARO's full-year earnings has moved 13.10% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, TARO has gained about 8.93% so far this year. At the same time, Medical stocks have gained an average of 0.73%. As we can see, Taro Pharmaceutical Industries is performing better than its sector in the calendar year.
To break things down more, TARO belongs to the Medical - Drugs industry, a group that includes 163 individual companies and currently sits at #108 in the Zacks Industry Rank. Stocks in this group have gained about 4.50% so far this year, so TARO is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to TARO as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TARO - FREE